NASDAQ : EPRX

Eupraxia Pharmaceuticals Inc. — Company profile

Healthcare · Biotechnology · Canada

Last price 6.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 449.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Details

NameEupraxia Pharmaceuticals Inc.
SectorHealthcare
IndustryBiotechnology
Employees49
Founded2011
CeoJames Helliwell
CountryCanada
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA29842P1053
Cusip29842P105
Cik1581178
Sic2834

Key executives

NameTitle
Dr. James A. Helliwell FRCPC, M.D.Chief Executive Officer and Director
Alexander John Rothwell Eng., M.B.A.Chief Financial Officer
Paul Anthony Brennan B.Sc., M.Sc.Chief Corporate Development Officer
Wajida Leclerc B.A., CCP, CHRPExecutive Vice President Corporate Services and People
Alex TherienExecutive Vice President of Research & Development
Dr. Jeymi Tambiah M.S.Chief Medical Officer
Dr. Jeffrey Millard Ph.d.Executive Vice President of Technical Operations

Contact

Address2067 Cadboro Bay Road, Suite 201, Victoria, BC V8R 5G4, Canada
Phone250 590 3968
Websitehttps://www.eupraxiapharma.com